article thumbnail

Supreme Court blocks Purdue Pharma's bankruptcy settlement, threatening immunity to Sackler family

Fierce Pharma

It’s been a rough summer for pharmaceutical companies trying to resolve lawsuits by declaring bankruptcy. | The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis.

article thumbnail

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

It is claimed to have outperformed an antiviral drug in lowering various proinflammatory mediators linked to hyperinflammation and dysfunction of the immune system after viral infection. Qifenda is a broad-spectrum antiviral drug in the commercial stage. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Pharmaceutical Technology

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

article thumbnail

Boehringer Ingelheim to advance bacterial cancer therapeutics

European Pharmaceutical Review

Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. Overall, the process enables the design of immuno-oncology combination therapies in one single agent.

article thumbnail

Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval

Pharmaceutical Technology

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.